SelectQuote's cash-flow double-down meets a skeptical tape
Operating cash flow guided to double to $60M+ while the equity trades down 25% in 90 days — a micro-cap betting its 'disconnect' gets resolved on the back of a shrinking P&L
SLQT · Earnings Call · 2026-08-25
The valuation disconnect, stated bluntly
SelectQuote is making its boldest equity pitch in years, and it centers on a single number: fiscal 2027 operating cash flow guided to roughly double to $60 million-plus, with free cash flow of around $50 million. That guidance — the first explicit operating-cash-flow guide the company has issued — follows a $44 million year-over-year improvement in fiscal 2026. The framing was unambiguous:
we expect SelectQuote to approximately double operating cash flow in fiscal 2027 to $60 million plus. We also believe the business will generate free cash flow of around $50 million.
The equity has been voting the other way. The stock is down ~98% from its April 2021 peak, and over the last 90 days into this report it has fallen another 25% from a May high, extending a drawdown to ~56%. At roughly 0.07x trailing revenue, the market prices the entire $1.62B-revenue platform at a small fraction of a year's sales. Management made that gap the centerpiece of its prepared remarks:
To be blunt, we see a wide disconnect in the value of our shares relative to the real cash flow generation of our platform.
The tension is real: fiscal 2027 revenue is guided down ~14% (to $1.35–1.45B) and adjusted EBITDA down from $109M to a $90–115M range, even as cash flow is guided to double. The company's cash generation story is thus a deliberate trade — revenue for cash — and the market has yet to underwrite it.
Healthcare Services: the margin inflection hiding a revenue pullback
The most consequential structural event this quarter is that Healthcare Services (SelectRx) has, for the first time, become SelectQuote's largest revenue contributor, at $845M versus Senior's $576M. That segment is now the engine of the cash-flow thesis, exiting fiscal 2026 at an annual EBITDA run rate of "nearly $50 million" — a target the company explicitly teed up in prior quarters ("we do expect the business will produce north of $50 million in EBITDA in fiscal 2026," the CFO said last August; and in May: "we are highly confident that in the very near term, this business will be at a $40 million to $50 million EBITDA run rate business"). What's new is the confidence in 2027: margins guided to approximately double year over year.
The drivers are operational, not volume-based. Membership is guided roughly flat, as the company concentrates on members with the best unit economics. The margin expansion comes from the pharmacy management system and the Kansas distribution facility, which management says is already “about 30% more efficient than our other sites” — Robert Grant, Unknown · 2026-08-25. Meanwhile the Inflation Reduction Act, in effect since January 1, 2026, is a persistent top-line headwind — Healthcare Services revenue is guided down 10–15% in 2027 — but management stresses the EBITDA impact is minimal because manufacturer refunds flow through cost of goods. The segment is therefore shrinking its top line while roughly doubling margins. Doubling of margins is the new operative phrase.
The counterweight is Medicare Advantage. The company frames the market as "healing" — “we are seeing a healing in the MA market. There's been year-over-year improvement, but there's still work to do” — Timothy Danker, Chief Executive Officer · 2026-08-25 — yet still expects carrier MLRs to remain elevated and plan disruptions to continue, guiding approved MA policies down 10–15% in 2027 as it "matches the market in prudence." The Senior engine, the other half of the cash-flow story, is deliberately being throttled.
The balance-sheet lever: $8 million per 100 basis points
The third pillar is financial engineering on a heavy capital stack. Management highlights ~$800M of debt and preferred equity at an approximate 12% cost, with ~$45M of annual cash interest, and quantifies the refinancing prize: “every 100-basis-point decrease in that overall funding cost would equate to nearly $8 million of savings that accretes to equity holders.” — Timothy Danker, Chief Executive Officer · 2026-08-25Receivables at 54.4% of revenue
With the receivable balance — the $1 billion-plus commissions receivable — expected to stay roughly flat as new policies replace collections, the company aims to use growing cash flow to both delever and, eventually, refinance. Liabilities-to-assets have improved to 50.3%, down 6.7 points year over year (Liabilities-to-Assets at 50.3%), and the securitization infrastructure remains "a path that's available to us" — though near-term probability is low given the disruptive Medicare cycle. That language is unchanged from prior quarters, when the CFO noted "securitization is still very much a path."
SelectQuote is also notably off the market's current beat. This week's earnings reporters — Walmart, Ross, Buckle, NSSC and others — have been dominated by IEEPA Tariff Refund dynamics, and the global 20263 keyword charts are saturated with tariff themes. SelectQuote's call contains none of that; it is entirely domestic and structural, resting on Medicare Advantage volatility, IRA drug pricing, and its own cost base. The company is marching to its own drummer.
The 90-day slide into this report suggests the market is not yet convinced the cash-flow doubling is real, durable, or sufficient against a ~12% cost of capital and still-elevated leverage. But SelectQuote has now put a precise, repeatable number on the destination — cash flow over time — and made the equity-valuation disconnect its explicit investment thesis. Whether that converts into a re-rating is, before anything else, a test of whether the market believes the ~$50 million free-cash-flow guide.